A Study of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone in People With Head and Neck Squamous Cell Carcinoma (HNSCC)

Full Title

An Open-Label Phase II/III Randomized Trial of BNT113 in Combination with Pembrolizumab versus Pembrolizumab Monotherapy as a First Line Therapy in Patients with Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Winston Wong’s office at 646-608-4245.